Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: 3-(2,4-dimethoxybenzylidene)anabaseine

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia

Exclusion Criteria:

• History of cardiovascular illness or neurological illness other than schizophrenia

• Current substance abuse, including nicotine

• History of clozapine use